

Udenyca[®] Onbody[™] (pegfilgrastim-cbqv) – First-time biosimilar launch

- On February 21, 2024, <u>Coherus announced</u> the launch of <u>Udenyca Onbody (pegfilgrastim-cbqv)</u>, a biosimilar to Amgen's <u>Neulasta® OnPro® (pegfilgrastim)</u>.
- Udencya Onbody and Neulasta OnPro share the following indications in adult patients:
 - Decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia
 - Increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Subsyndrome of Acute Radiation Syndrome).



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.